ArticleCell death & disease2026
Remodeling of ferroptotic necroinflammation by dexamethasone in acute tubular necrosis.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Ferroptosis, a modality of regulated necrosis caused by iron-dependent lipid peroxidation, has emerged as a key contributor to the pathogenesis of acute tubular necrosis (ATN) - especially in the context of solid organ transplantation. While recent studies have identified hormones as extracellular signals that modulate cellular susceptibility to ferroptosis, their pathophysiological relevance in vivo remains incompletely defined. Here, we investigated the role of dexamethasone, a potent synthetic glucocorticoid previously reported to sensitize cells to ferroptosis, in the context of renal tubular injury. Unexpectedly, we observed a biphasic effect: early sensitization to ferroptosis induced by glutathione depletion was subsequently counteracted by a marked increase in ferroptosis resistance. Mechanistically, we found that dexamethasone reduced availability of ferrous iron via effects of the glucocorticoid receptor 1 (GR1), which also resulted in attenuated renal tubular injury. However, this cytoprotective effect did not translate into improved renal function, as dexamethasone exerted additional ferroptosis-independent effects on innate immune cell recruitment to injured kidneys. Collectively, our findings highlight the highly dynamic nature of the ferroptotic process in which modulatory signals can exert temporally opposing effects. Moreover, they underscore the complex interplay between regulated cell death and innate immune responses in shaping necroinflammation in disease trajectories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.